Fundraising FoxYsios Capital — 2017 Investments
4 investments dated 2017 · listed companies and verified rows first · show all
Amgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesThousand Oaks, US
Sanford Markowitz(Director)William K. Bowes(Founder)George B. Rathmann(First CEO)David Piacquad(Executive Officer)Brian M. McNamee(Executive Officer)inRobert A. Bradway(Executive Officer, Director)
Co-investorsAsset Management CompanyBOMBoulder VenturesCWRU Technology VenturesIndustrifondenMayfield Fund+5 more
Acqustic is a music community platform connecting independent musicians, industry companies, brands, and fans, offering new releases, concerts, videos, and playlists.
ConsumerMedia & EntertainmentSocial
Esteve Lombarte Llado(Founder)in
Co-investorsCOREangelsDraper B1
Babyscripts provides a maternity care platform with remote patient monitoring, risk screening, and care management services for pregnant and postpartum patients.
Digital HealthFemTechHealthtechSaaS
Juan Pablo Segura(Founder)inAnish Sebastian(Founder & CEO)in
Co-investorsCU Healthcare Innovation FundMemorialCare Innovation FundPhilips VenturesAAF Management Ltd.Builders + BackersCivilization Ventures Management, Llc+5 more
Takeda is a global pharmaceutical company that develops medicines and treatments for patients, focused on advancing science, technology, and partnerships to create new standards of care.
BiotechHealthtechTokyo, JP
Claudia D'Augusta(Executive Officer)inEduardo Bravo Fernandez de Araoz(Executive Officer, Director)Marie Paule Richard(Executive Officer)inWilfried Dalemans(Executive Officer)
BoardJune Almenoff(Director)Russell Greig(Director)
Co-investorsKleiner PerkinsRho VenturesRoche Venture FundBrightlands Venture PartnersKreos Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.